EcN-Sj16-Exo ameliorates experimental asthma by inhibiting eosinophil extracellular traps formation via N-WASP upregulation

BACKGROUND: with known immunoregulatory properties. Exosomes, with their protective phospholipid bilayer, serve as efficient drug carriers. METHODS: ) knockout mice and recombinant adeno-associated virus (rAAV)-expressing Neural Wiskott-Aldrich syndrome protein (N-WASP) were used to investigate the potential mechanisms of EcN-Sj16-Exo. RESULTS: knockout mice and AAV6-WASL-mediated N-WASP expression confirmed that EcN-Sj16-Exo alleviates experimental asthma by upregulating N-WASP to inhibit EET formation. CONCLUSION: Our findings suggest that EcN-Sj16-Exo represents a promising therapeutic approach in asthma, highlighting the potential of targeting EETs and N-WASP in asthma therapy.